Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Current Status of Next-Generation Sequencing-Based Cancer Genome Profiling Tests in Japan and Prospects for Liquid Biopsy

6 Aug 2021

Abstract excerpt

Next-generation sequencing-based comprehensive genome profiling (CGP) testing, OncoGuide NCC Oncopanel System, and FoundationOne CDx Cancer Genomic Profile have been covered by the Japanese national health insurance system since June 2019. Because CGP was initially developed to enroll patients into an early-phase clinical trial for solid tumors, its approved indications have been limited to patients who have...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Lung Cancer Treatments and Mutations
Share to Pancreatic and Hepatic Oncology Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34440540
DOI: 10.3390/life11080796

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Current Status of Next-Generation Sequencing-Based Cancer Genome Profiling Tests in Japan and Prospects for Liquid BiopsyPMID 34440540Read ↗

Regulatory perspectives on next-generation sequencing and complementary diagnostics in Japan.Semantic proximity Read ↗

A Pilot Study Analyzing the Clinical Utility of Comprehensive Genomic Profiling Using Plasma Cell-Free DNA for Solid Tumor Patients in Japan (PROFILE Study).Semantic proximity Read ↗

Application of next-generation sequencing technology to precision medicine in cancer: joint consensus of the Tumor Biomarker Committee of the Chinese Society of Clinical OncologySemantic proximity Read ↗

Clinical utility of Todai OncoPanel in the setting of approved comprehensive cancer genomic profiling tests in JapanSemantic proximity Read ↗

Appropriate use of cancer comprehensive genome profiling assay using circulating tumor DNA.Semantic proximity Read ↗

Clinical Utility and Benefits of Comprehensive Genomic Profiling in Cancer.Semantic proximity Read ↗

Multiplex gene-panel testing for lung cancer patients.Semantic proximity Read ↗

Clinical and diagnostic utility of genomic profiling for digestive cancers: real-world evidence from JapanSemantic proximity Read ↗

Current practices and guidelines for clinical next-generation sequencing oncology testing.Semantic proximity Read ↗

New Era for Next-Generation Sequencing in JapanSemantic proximity Read ↗

Next-generation sequencing in cancer diagnosis and treatment: clinical applications and future directionsSemantic proximity Read ↗

The emerging roles of NGS in clinical oncology and personalized medicine.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.